Key Players in the South Korea Atherosclerosis Market | Top Companies & Insights 2026

Q: Which company leads in the South Korea Atherosclerosis market?

Hanmi Pharmaceutical and Yuhan Corporation are the major local brands, while Pfizer and AstraZeneca maintain market share through global brand recognition.

Q: How are digital health tools being integrated by leading players in South Korea?

Leading companies are investing in digital initiatives, to help patients manage chronic cardiovascular risks.

Q: What are the primary therapeutic areas for leading companies like Hanmi and Daewoong in South Korea?

Major players such as Hanmi and Daewoong are focused on fixed-dose combination therapies that treat both hypertension and dyslipidaemia simultaneously.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA12016

Publication Date: Apr 2026

Key Players in the South Korea Atherosclerosis Market

The South Korea atherosclerosis market is a critical segment of the healthcare sector, featuring a mix of multinational pharmaceutical giants and prominent domestic distributors. These players compete for the larger market share by developing advanced lipid-lowering therapies, anti-platelet medications, and fixed-dose combinations. Key companies driving the market include Hanmi Pharmaceutical Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Yuhan Corporation, and HK inno. N Corp.

For detailed forecasts, data tables, and competitive benchmarking,
Explore the full South Korea atherosclerosis market.

View Main Report Schedule Analyst Call

South Korea Atherosclerosis Market Overview

According to 6Wresearch, the South Korea atherosclerosis market is set to witness significant growth, spurred by the rising older population and an increase in cardiovascular conditions. Atherosclerosis, is known as the build-up of fats and cholesterol in the walls of artery, and remains as a major cause behind strokes and heart attacks.

The market is influenced by government initiatives that are aimed at improving healthcare infrastructure and the demand for high-quality chronic disease management. There is a significant shift towards preventive cardiology and the adoption of sophisticated diagnostic tools.

Competitive Landscape

The competitive landscape of the South Korea atherosclerosis industry is determined by the dominance of global biopharmaceutical giants along with a growing network of local manufacturing and distribution channels. Leading companies maintain an effective market share through extensive clinical data, brand trust, and strategic partnerships with hospital networks and retail pharmacies.

Below is a list of leading players operating in the South Korea Atherosclerosis Market:

1. Hanmi Pharmaceutical Co., Ltd.

Company Name	Hanmi Pharmaceutical Co., Ltd.
Established Year	1973
Headquarters	Seoul, South Korea
Official Website	Click Here

Hanmi is a major player in the market, known for its fixed-dose combination and a robust portfolio of lipid-lowering therapies.

2. Daewoong Pharmaceutical Co., Ltd.

Company Name	Daewoong Pharmaceutical Co., Ltd.
Established Year	1945
Headquarters	Seoul, South Korea
Official Website	Click Here

Daewoong maintains a strong presence through its innovative cardiovascular solutions and blockbuster treatments.

3. Yuhan Corporation

Company Name	Yuhan Corporation
Established Year	1926
Headquarters	Seoul, South Korea
Official Website	Click Here

The company focuses on metabolic and cardiovascular diseases, offering a wide range of statins and anti-hyperlipidaemic treatments.

4. HK inno. N Corp.

Company Name	HK inno. N Corp.
Established Year	1984
Headquarters	Seoul, South Korea
Official Website	Click Here

HK inno. N is a leader in providing essential treatments for chronic conditions, including cardiovascular medicines targeting cholesterol management.

5. JW Pharmaceutical

Company Name	JW Pharmaceutical
Established Year	1945
Headquarters	Seoul, South Korea
Official Website	Click Here

JW Pharmaceutical provides the original "Livalo" treatment, used in the prevention and management of atherosclerosis-related events.

6. Boryung Co., Ltd.

Company Name	Boryung Co., Ltd.
Established Year	1963
Headquarters	Seoul, South Korea
Official Website	-

Boryung is a key supplier of cardiovascular pharmaceuticals, particularly known for its proprietary family of medicines.

7. GC Biopharma

Company Name	GC Biopharma
Established Year	1967
Headquarters	Yongin, South Korea
Official Website	Click Here

GC Biopharma is involved in the distribution of specialty medicines and diagnostic tools that target various risk factors associated with atherosclerosis.